USA flag logo/image

An Official Website of the United States Government

A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
89468 		Program Year/Program:
2008 / STTR
Agency Tracking Number:
AI073064 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
MOLECULAR TARGETING TECHNOLOGY, INC.
833 LINCOLN AVE, UNIT 9 WEST CHESTER, PA 19380-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
Agency: HHS
Contract: 1R41AI073064-01A1
Award Amount: $669,400.00
 

Abstract:

DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, a lthough there are major vaccine development initiatives ongoing, there currently is no approved Botulinum toxin vaccine available. Advances in Botulinum research have designated the optimal target for vaccine development to be the non-toxic carboxyterminal half of the toxin heavy chain (HC50). In fact, an immediate research goal for NIAID is listed as the development of a HC50 fragment vaccine against botulinum neurotoxins. Therefore, this phase I research project proposes an innovative approach to the deve lopment of a botulinum toxin vaccine in that it will use recombinant technology to express the BoNT HC50 on the virion surface of rabies virus (RV) for use as a potential vaccine. The hypothesis, supported by multiple studies with RV, is that use of the ki lled RV containing the HC50 as a vaccine will greatly enhance the immune responses compared to using HC50 alone. RV has many attributes that make it an ideal candidate for a delivery vector for vaccine immunogens. This project proposes to 1) construct reco mbinant RVs expressing a chimeric RV G protein containing BoNT HC50, 2) characterize the immune response of mice immunized with the inactivated RV BoNT HC50 constructs to assess its extent and potency, and 3) challenge RV BoNT HC50-immunized mice with BoNT /A toxin to assess the level of vaccine protection.

Principal Investigator:

Business Contact:


cpak@mtarget.com
Small Business Information at Submission:

MOLECULAR TARGETING TECHNOLOGY, INC.
833 Lincoln Ave., Unit 9 WEST CHESTER, PA 19380

EIN/Tax ID: 123310246
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No